Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis
Authors' conclusion
Gla-100 and Gla-300 had comparable efficacy and safety profiles in both T1D and T2D populations. Gla-300 showed a lower risk of nocturnal and total hypoglycaemia, significant in insulin-experienced/exposed patients with T2D. Patients on Gla-300 required significantly more units of insulin daily than the Gla-100 group to achieve equivalent efficacy.
Study context
- Population
- Adults with T2D and T1D; parallel-design Randomized Controlled Trials (RCTs) (MEDLINE/Embase/Cochrane to 10 January 2021)15 RCTs
- Comparison
- Gla-300 vs Gla-100
- Outcome
- Efficacy and safety
Methodological detailsrandom-effects model, Cochrane risk-of-bias tool
- Random-effects model
- Cochrane risk-of-bias tool
Pooled result
As reported in the abstract
- T1D: all safety parameters comparable between Gla-100 and Gla-300
- T2D: significant differences favouring Gla-300 for nocturnal and total hypoglycaemia
- Statistically and clinically significant difference favouring Gla-100 in basal insulin dose requirement in T2D and T1D
- T1D: statistically but not clinically significant HbA1c reduction with Gla-100 vs Gla-300
- Statistically significant but clinically less relevant differences favoured Gla-300 for body weight in T1D and T2D, and Gla-100 for fasting blood glucose in T2D
- T2D: 10 RCTs, n = 7082; T1D: 5 RCTs, n = 2222
Safety
- T1D: all safety parameters comparable
- T2D: nocturnal and total hypoglycaemia significantly favoured Gla-300
Original publication
Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis. Diabetes Obes Metab. Published 28 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →